Early Aspirin Withdrawal After PCI in ACS: NEO-MINDSET and TARGET Trials
Christopher Cannon, Senior Physician in the Cardiovascular Division at Brigham and Women’s Hospital, shared a post on LinkedIn:
”Keep the ASA for the first 12 months post ACS PCI.
The NEO-MINDSET trial found that early stopping and keeping P2Y12 monotherapy was NOT sufficient for efficacy.
Of note, another study published, the TARGET First looked at “low risk” STEMI patients and suggested one could stop ASA, but it appeared to have much less power with just 41 primary endpoints.
So – I will aim to keep DAPT for a year post PCI for ACS. (although sometimes one has to adapt for very high risk bleeding patients).”
Title: Early Withdrawal of Aspirin after PCI in Acute Coronary Syndromes
Authors: Patricia O. Guimarães, Marcelo Franken, Caio A.M. Tavares, Murillo O. Antunes, Fabio S. Silveira, Pedro B. Andrade, Ricardo R. Bergo
Read the full article here.
Find more on Hemostasis Today.
-
Aug 23, 2026, 17:51Gurpreet Kaurr: A Proud Milestone in Haematology and Oncology
-
Aug 23, 2026, 17:33Kathrine Kaspersen: How Voluntary Plasma Donors Helped Transform Denmark’s Plasma Supply
-
Aug 23, 2026, 16:51Sthanu Subramanian: Empagliflozin and a Rise in Hematocrit
-
Aug 23, 2026, 16:50Lale Tokgözoğlu: New PCSK9i Research Published in the European Heart Journal
-
Aug 23, 2026, 16:44Eric Gehrie: Your 2026 Guide to the Essentials of Transfusion Medicine
-
Aug 23, 2026, 16:35Thomas Dayspring: The Overlooked Pathway in Cholesterol Homeostasis
-
Aug 23, 2026, 16:28Evan Mapelu: The People Who Make Cancer Care Meaningful
-
Aug 23, 2026, 16:09Felice Gragnano: New Publication on Aspirin Discontinuation After PCI for Acute Coronary Syndromes
-
Aug 23, 2026, 16:06Mostafa Faisal: Donor Type and Long-Term Quality of Life After HCT for Severe Aplastic Anemia